ASXL1 and chronic myelogenous leukemia, BCR-ABL1 positive: There was no significant difference in OS in our cohort based on the mutational profile of the patients (Fig. 2C), albeit a trend of worse OS in patients with mutated ASXL1 when considering only CML-related mortality (Supplemental Fig. 3C).